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and Göteborg, SwedenOBJECTIVES The aim of this study was to report the frequency, patient and lesion-related charac-
teristics, and outcomes of subclinical, nonculprit plaque ruptures in the PROSPECT (Providing Regional
Observations to Study Predictors of Events in the Coronary Tree) study.
BACKGROUND Plaque rupture and subsequent thrombosis is themost commoncauseof acute coronary
syndrome (ACS). Secondary, subclinical, nonculprit plaque ruptures have been seen in both stable patients and
patients with ACS; however, reports of the natural history of these secondary plaque ruptures are limited.
METHODS After successful stenting in 697 patients with ACS, 3-vessel grayscale and intravascular
ultrasound virtual histology (IVUS-VH) was performed in the proximal-mid segments of all 3 coronary ar-
teries as part of a prospective multicenter study.
RESULTS Among 660 patients with complete IVUS data, 128 plaque ruptures were identiﬁed in 105
nonculprit lesions in 100 arteries from 93 patients (14.1%). Although the minimum lumen area (MLA)
was similar, the plaque burden was signiﬁcantly greater in nonculprit lesions with a plaque rupture
compared with nonculprit lesions without a plaque rupture (66.0% [95% conﬁdence interval: 64.5% to
67.4%] vs. 56.0% [95% conﬁdence interval: 55.6% to 56.4%]; p < 0.0001). IVUS-VH analysis revealed that
a nonculprit lesion with a plaque rupture was more often classiﬁed as a ﬁbroatheroma than a nonculprit
lesion without a plaque rupture (77.1% vs. 51.4%; p< 0.0001). Independent predictors of a plaque rupture
were lesion length (per 10 mm; odds ratio: 1.30; p< 0.0001), plaque burden at the MLA site (per 10%; odds
ratio: 2.56; p < 0.0001), vessel area at the MLA site (per 1 mm2; odds ratio: 1.13; p < 0.0001), and VH–
thin-cap ﬁbroatheroma (odds ratio: 1.80; p ¼ 0.016). During 3 years of follow-up, the incidence of overall
major adverse cardiac events did not differ signiﬁcantly between the patients with and patients without
subclinical, nonculprit plaque ruptures.
CONCLUSIONS Secondary, nonculprit plaque ruptureswere seen in14%ofpatientswithACSandwere
associated with a ﬁbroatheroma phenotype with a residual necrotic core but not with adverse outcomes
if patients were treated with optimal medical therapy as part of a multicenter study. (Providing Regional
Observations to Study Predictors of Events in the Coronary Tree [PROSPECT]; NCT00180466) (J Am Coll
Cardiol Img 2014;7:397–405) ª 2014 by the American College of Cardiology FoundationFrom the *Division of Cardiology, Columbia University Medical Center, New York, New York; yClinical Trials Center,
Cardiovascular Research Foundation, New York, New York; zDepartment of Cardiology, Northern Jiangsu People’s Hospital,
Yangzhou University, Yangzhou, China; xInterventional Cardiology Unit, Hospital Meixoeiro, Vigo, Spain; kDivision of
Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York; {Department of Cardiology, Thoraxcenter,
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398he most common cause of an acute coronary committee at each participating center, and all pa-
syndrome (ACS) is rupture of an athero-
sclerotic lesion followed by acute luminal
thrombosis (1,2). Pathological studies have
suggested that the precursor of a ruptured plaque is
a thin-cap ﬁbroatheroma (TCFA). Although in vivo
studies of TCFAs and their evolution into a
ruptured plaque are rare, intravascular ultrasound
(IVUS) studies (3,4) have reported that a plaque
rupture occurs not only in culprit lesions but also in
nonculprit or secondary atherosclerotic plaques in
patients with ACS. Reports of the natural history of
these secondary plaque ruptures are limited and include
only small numbers of patients (5–7). The present
study uses the 3-vessel IVUS data from the PROS-
PECT (Providing Regional Observations to Study
Predictors of Events in the Coronary Tree) study to
assess the prevalence, clinical features, angiographic
appearance, IVUS–virtual histology (VH) morphology,Erasmus Me
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METHODS
Patient selection and protocol. The
enrollment criteria and methodology of the
PROSPECT study have been described
in detail (8). Brieﬂy, 697 patients with
ACS (ST-segment elevation myocardial
infarction >24 h, non–ST-segment ele-
vation myocardial infarction, or unstable
angina with electrocardiographic changes)
underwent coronary angiography and
multimodality intracoronary imaging of theproximal 6 to 8 cm of all 3 coronary arteries after
treatment of the culprit lesion and any other planned
interventions. Patients were then followed up for a
median of 3.4 years to relate subsequent events to the
morphologies of the lesions detected at baseline.
Medications, including dual antiplatelet therapy
and statin therapy, were recorded at discharge and
during follow-up. The study was approved by the
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tients enrolled in the PROSPECT study, 660
patients with complete grayscale and IVUS-VH data
comprised the current study population.
Quantitative coronary angiography and IVUS. In-
tracoronary imaging, both grayscale and IVUS-VH,
was performed with the use of a synthetic aperture
array, 20-MHz, 3.2-F catheter (Eagle Eye, In-
Vision Gold, Volcano Corp., Rancho Cordova,
California) with motorized catheter pullback (0.5
mm/s). Baseline angiographic as well as grayscale
and IVUS-VH images were analyzed at the Car-
diovascular Research Foundation (New York, New
York) in a core laboratory that was blinded to the
clinical outcomes. Off-line grayscale and IVUS-VH
analyses of all imaged segments were performed
prospectively at an independent IVUS core labora-
tory at the Cardiovascular Research Foundation by
investigators who were blinded to the angiographic
analysis and to the clinical events. Detailed angio-
graphic and grayscale and IVUS-VH methodology
has been described previously (9).
An IVUS nonculprit lesion was deﬁned as a
plaque burden of $40% in at least 3 consecutive
frames. Lesions were considered separate if there
was a $5-mm-long segment with <40% plaque
burden between them. A plaque rupture was deﬁned
as a cavity that communicated with the lumen with
an overlying residual ﬁbrous cap fragment (Fig. 1).
One lesion could have multiple plaque ruptures.
Rupture sites separated by $3 consecutive frames
(approximately 1.5 mm) of artery containing smooth
lumen contours and no cavity were considered to
represent discrete and separate plaque ruptures.
On the basis of IVUS-VH, plaque components
were categorized as dense calcium, ﬁbrous tissue,
ﬁbrofatty plaque, or necrotic core and reported as
percentages of total plaque areas and volumes.
Lesions were then classiﬁed by IVUS-VH as 1
of the following: VH-TCFA, thick-cap ﬁbroather-
oma (ThCFA), pathological intimal thickening,
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Figure 1. The Residual VH–Thin-Cap Fibroatheromas and Necrotic Cores Around the Rupture Site
In example 1, a, b, and c are virtual histology (VH) images corresponding to the grayscale panels A, B, and C. B (b) is the rupture site (arrow)
containing the largest cavity. A (a) and C (c) are proximal and distal to the rupture site. In c, a thin-cap ﬁbroatheroma is observed (arrow). In
another case (example 2), d, e, and f are VH images corresponding to the grayscale panels D, E, and F. E (e) is the rupture site (arrow)
containing the largest cavity. A thin-cap ﬁbroatheroma is observed in d (arrow). VH intravascular ultrasonography plaque components are
color coded as dense calcium (white), necrotic core (red), ﬁbrofatty (light green), or ﬁbrous tissue (dark green). (The red in the cartoon is
designed to show the longitudinal distribution of the necrotic core and is not to scale.)
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 4 , 2 0 1 4 Xie et al.
A P R I L 2 0 1 4 : 3 9 7 – 4 0 5 Nonculprit Plaque Morphology and Outcome
399reported. Fibroatheromas were subclassiﬁed as
having single or multiple conﬂuent necrotic cores.
The total length of each VH-TCFA was analyzed
and summed per lesion.
Clinical endpoints and deﬁnitions. The primary
endpoint was the incidence of major adverse car-
diovascular events (MACE) (the composite of deathfrom cardiac causes, cardiac arrest, myocardial
infarction, or rehospitalization due to unstable or
progressive angina according to the Braunwald
classiﬁcation of unstable angina and the Canadian
Cardiovascular Society classiﬁcation of angina). The
primary endpoint was adjudicated by an indepen-
dent clinical events committee. On the basis of
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400follow-up angiography, MACE were attributed to a
nonculprit lesion site if the site associated with an
event was previously untreated. If follow-up angi-
ography was not performed, the lesion site was
classiﬁed as indeterminate and was excluded from
this analysis.
Statistical analysis. All statistical analyses were
performed using SAS version 9.2 (SAS Institute
Inc., Cary, North Carolina). Categorical variables
were summarized using percentages and counts and
were compared using chi-square statistics or Fisher
exact test where appropriate. Continuous variables
were compared using analysis of variance and un-
paired t tests. For ﬁbroatheroma and lesion-level
data, a model with a generalized estimating equa-
tion approach was used to compensate for potential
cluster effects of multiple lesions in the same patient
and presented as least squares means with 95%
conﬁdence intervals (CIs). Multivariate logistic
regression analysis was used to determine indepen-
dent predictors of a plaque rupture. Kappa statistics
were used to assess the interobserver and intra-
observer variability for qualitative analyses. A p value
of <0.05 was considered statistically signiﬁcant.
RESULTS
Patients and baseline characteristics. Among 660
patients with complete IVUS data, 128 nonculprit
plaque ruptures were identiﬁed in 105 nonculprit
lesions in 100 arteries from 93 patients (14.1%).
Among the 105 nonculprit lesions with a plaque
rupture, 40 (38%) were located in the culprit vessel
and 65 (62%) in the nonculprit vessel. There was no
difference of lesion morphology between them (data
not shown). Overall, 49% of ruptured plaques were
located in the right coronary artery (n ¼ 63), 35% in
the left anterior descending artery (n ¼ 45), and
16% in the left circumﬂex artery (n ¼ 20). Intra-
observer and interobserver concordance for the
detection of plaque ruptures was good (kappa: 0.90
[0.59 to 1.0] and 0.85 [0.54 to 1.0]). Table 1 shows
the baseline characteristics of the 93 patients with at
least 1 nonculprit plaque rupture compared with the
567 patients without a detectable nonculprit plaque
rupture. Patients with a plaque rupture were more
likely to be male, have had a prior cardiac inter-
vention, and have a higher body mass index.
Although the prevalence of hypercholesterolemia
requiring medication was similar between the
2 groups, the lipid proﬁle tended to be worse in
patients with a plaque rupture (total cholesterol:
184.0 mg/dl [155.0 to 205.0 mg/dl] vs. 169.0 mg/dl
[147.0 to 197.0 mg/dl], p ¼ 0.02; triglycerides:145.0 mg/dl [100.5 to 196.0 mg/dl] vs. 122.0 mg/dl
[88.6 to 177.1 mg/dl], p ¼ 0.02). Other risk factors,
such as diabetes, hypertension, and smoking, were
similar between the 2 groups. The clinical presen-
tation did not differ between the 2 groups.
Patient-level angiographic and IVUS analysis.
Angiographically, patients with a plaque rupture
showed a trend toward more and longer nonculprit
lesions (Table 2). There was no difference in the
angiographic qualitative parameters between the 2
groups except that there was a trend for patients
with plaque ruptures to have more aneurysmal
lesions (p ¼ 0.09). By IVUS, the percent total
plaque volume (total plaque volume divided by
external elastic membrane volume over the com-
bined lengths of the lesions identiﬁed in each pa-
tient) was signiﬁcantly greater in patients with at
least 1 nonculprit plaque rupture than in patients
without a plaque rupture (51.1% [48.5% to 53.2%]
vs. 48.9% [46.5% to 51.7%]; p < 0.0001). Patients
with at least 1 secondary plaque rupture were more
likely to have at least 1 nonculprit lesion with a
plaque burden $70% (50.5% vs. 30.5%;
p ¼ 0.0001). IVUS-VH analysis showed that there
were more VH-TCFAs in patients with at least
1 nonculprit plaque rupture than in patients without
a plaque rupture (p ¼ 0.01).
Lesion-level grayscale IVUS analysis. Overall, there
were 3,229 nonculprit lesions with a plaque burden
$40% identiﬁed by IVUS; among these lesions, 128
plaque ruptures were identiﬁed in 105 lesions (4%).
IVUS analysis showed that a nonculprit lesion with
a plaque rupture was twice as long as a lesion
without a plaque rupture (29.7 mm [95% CI: 26.7
to 32.8 mm] vs. 15.4 mm [95% CI: 14.9 to 16.0
mm]; p < 0.0001). Lesions with a plaque rupture
had a greater percent plaque volume than did lesions
without a plaque rupture (53.4% [95% CI: 52.5% to
54.3%] vs. 48.3% [95% CI: 48.0% to 48.5%]; p <
0.0001). Although the minimum lumen area
(MLA) was similar in both groups (secondary le-
sions with vs. without a plaque rupture), the plaque
burden at the MLA site and area stenosis (along
with a larger external elastic membrane area) were
signiﬁcantly greater in the plaque rupture group
(66.0% [95% CI: 64.5% to 67.4%] vs. 56.0% [95%
CI: 55.6% to 56.4%]; p < 0.0001) compared with
the nonplaque rupture group (40.5% [95% CI:
37.9% to 43.2%] vs. 26.5% [95% CI: 25.9% to
27.2%]; p < 0.0001) (Table 3).
Lesion-level IVUS-VH analysis. IVUS-VH analysis
revealed that a nonculprit lesion with a plaque rupture
was more often classiﬁed as a ﬁbroatheroma than
a nonculprit lesion without a plaque rupture (77.1%
Table 1. Clinical Characteristics of Patients With Versus Without a Plaque Rupture
Patients With
at Least 1 Plaque
Rupture Lesion
(n [ 93)
Patients Without
a Plaque Rupture
Lesion
(n [ 567)
p
Value
Age, yrs 57.9 (48.7–66.6) 58.2 (51.0–67.2) 0.39
Male 89.2 (83) 75.0 (425) 0.002
Diabetes mellitus 16.1 (15) 17.4 (98) 0.77
Metabolic syndrome 52.2 (47) 47.6 (261) 0.42
Hypertension 47.8 (44) 46.4 (261) 0.81
Hypercholesterolemia 46.0 (40) 44.7 (230) 0.83
Current smoker 57.1 (52) 46.3 (259) 0.054
Prior myocardial infarction 10.8 (10) 10.7 (60) 0.98
Prior cardiac intervention 16.1 (15) 9.9 (56) 0.07
Clinical presentation
STEMI >24 h 30.1 (28) 30.0 (170) 0.98
NSTEMI 66.7 (62) 66.1 (375) 0.92
Unstable angina 3.2 (3) 3.9 (22) 1.00
Body mass index, kg/m2 28.7 (26.3–32.3) 27.8 (25.1–31.0) 0.03
Estimated creatinine clearance, ml/min 108.5 (83.1–142.8) 97.1 (75.4–121.5) 0.010
Total cholesterol, mg/dl 184.0 (155.0–205.0) 169.0 (147.0–197.0) 0.02
HDL, mg/dl 38.6 (33.0–43.0) 38.6 (34.0–47.0) 0.39
Total cholesterol/HDL cholesterol 4.92 (3.80–5.77) 4.33 (3.54–5.20) 0.01
LDL cholesterol, mg/dl 107.2 (86.8–135.0) 99.4 (78.4–125.4) 0.08
Triglycerides, mg/dl 145.0 (100.5–196.0) 122.0 (88.6–177.1) 0.02
C-reactive protein, mg/l
Day 30 1.40 (0.80–3.95) 1.80 (0.80–4.00) 0.57
Day 180 1.65 (0.90–3.50) 1.40 (0.70–2.80) 0.29
Statins
Discharge 84.9 (79/93) 86.5 (489/565) 0.68
3 yrs 83.3 (65/78) 85.1 (400/470) 0.69
Aspirin
Discharge 97.8 (91/93) 96.6 (548/567) 0.75
3 yrs 89.7 (70/78) 91.9 (433/471) 0.52
Thienopyridines
Discharge 98.9 (92/93) 96.8 (549/567) 0.68
3 yrs 35.9 (28/78) 34.4 (162/471) 0.80
Values are median (1st–3rd quartiles), % (n), or % (n/N).
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; NSTEMI ¼ non–ST-segment elevation
myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 4 , 2 0 1 4 Xie et al.
A P R I L 2 0 1 4 : 3 9 7 – 4 0 5 Nonculprit Plaque Morphology and Outcome
401vs. 51.4%; p< 0.0001), whereas pathological intimal
thickening was more common in lesions without
a plaque rupture (36.8% vs. 19.0%; p ¼ 0.0004).
When subdivided into types of ﬁbroatheromas,
IVUS-VH indicated that a nonculprit lesion was
more often classiﬁed as a VH-TCFA than a non-
culprit lesion without a plaque rupture (38.1% vs.
21.7%; p < 0.0001). Furthermore, a lesion with a
plaque rupture that was identiﬁed as a ﬁbroatheroma
more often had multiple necrotic cores whether the
lesion was classiﬁed as a VH-TCFA or a ThCFA
(32.4% vs. 15.3% [p < 0.0001] and 36.2% vs. 24.6%
[p ¼ 0.005], respectively) (Table 4).
In 105 lesions with at least 1 plaque rupture,
1 lesion contained 3 discrete plaque ruptures,
21 lesions had 2 discrete plaque ruptures, and 83
lesions had 1 plaque rupture. Among these 128
plaque ruptures, when the image slice with the
largest plaque cavity was analyzed, there was a re-
sidual conﬂuent necrotic core in 62.5% of plaque
ruptures either at the bottom of the cavity or at the
shoulder of the cavity. A VH-TCFA was located
proximal to the cavity in 37.3% of the plaque rup-
tures, and a VH-TCFA was located distal to the
cavity in 32.5% of plaque ruptures so that 46.1% of
plaque ruptures had a VH-TCFA either proximal or
distal to the plaque rupture segment (Fig. 1).
Predictors of plaque rupture. Including patient and
lesion characteristics, we evaluated the independent
predictors for existence of rupture. After univariate
analysis, the following 10 variables (all of the vari-
ables with p < 0.1 in the univariate model) were
included in the ﬁnal multivariate model: white race,
body mass index, low-density lipoprotein cholesterol
level, triglyceride level, lesion length by IVUS, mean
dense calcium cross-sectional area (CSA) per lesion,
mean necrotic core CSA per lesion, plaque burden at
the MLA site, external elastic membrane CSA at the
MLA site, and VH-TCFA. Independent predictors
of plaque rupture were lesion length (per 10 mm;
odds ratio: 1.30 [95% CI: 1.15 to 1.46]; p< 0.0001),
plaque burden at the MLA site (per 10%; odds ratio:
2.56 [95% CI: 2.04 to 3.21]; p < 0.0001), external
elastic membrane CSA at the MLA site (per 1 mm2;
odds ratio: 1.13 [95% CI: 1.09 to 1.17]; p< 0.0001),
and VH-TCFA (odds ratio: 1.80 [95% CI: 1.11 to
2.89]; p ¼ 0.016).
Medications and clinical outcomes. There was no
difference in cardiac medications, including statin
therapy and dual antiplatelet therapy, between the
2 groups (patients with vs. without a secondary
plaque rupture) at discharge and during 3 years of
follow-up (Table 1). Table 5 summarizes the 3-year
clinical outcomes in patients with versus without aplaque rupture. During follow-up, 6 patients
developed a myocardial infarction, and 68 patients
were rehospitalized due to unstable or progressive
angina. The incidence of overall MACE, however,
did not differ signiﬁcantly between the 2 patient
groups. Nevertheless, there was a trend for lesions
with a plaque rupture to result in more nonculprit
MACE (4.0% vs. 1.8%; p ¼ 0.09) because of a
trend toward more rehospitalizations (4.0% vs.
1.7%; p ¼ 0.07).
Table 2. Angiographic and Grayscale and IVUS-VH Findings in Patients With Versus Without a Plaque Rupture
Patients With at Least
1 Plaque Rupture
(n [ 93)
Patients Without a
Plaque Rupture
(n [ 567) p Value
Total length of angiographic nonculprit lesions, mm 20.9 (11.2–42.3) 19.8 (7.9–36.6) 0.08
Number of angiographic nonculprit lesions 2.0 (1.0–4.0) 2.0 (1.0–4.0) 0.15
Number of IVUS nonculprit lesions 5.0 (4.0–6.0) 5.0 (3.0–6.0) 0.02
Patients with $1 lesion with MLA #4 mm2 55.9 (52) 55.4 (314) 0.92
Patients with $1 lesion with plaque burden $70% 50.5 (47) 30.5 (173) 0.0001
Patients with $1 VH-TCFAs 61.3 (57) 52.5 (271) 0.12
Plaque burden summed for all identiﬁed nonculprit lesions
per patient, %
51.1 (48.5–53.2) 48.9 (46.5–51.7) <0.0001
Necrotic core volume per patient, % 12.3 (8.4–17.8) 12.0 (7.5–17.7) 0.56
Values are median (1st–3rd quartiles) or % (n).
IVUS ¼ intravascular ultrasound; MLA ¼ minimum lumen area; TCFA ¼ thin-cap ﬁbroatheroma; VH ¼ virtual histology.
Table 3. Grayscale IV
Volumetric data
Lesion length, mm
Total plaque volum
Mean EEM CSA, mm
Mean lumen CSA, m
MLA site
EEM CSA, mm2
Lumen CSA, mm2
MLA #4 mm2
Plaque burden, %
Plaque burden $70
Remodeling index
Area stenosis, %
Distance from ostiu
Values are least squares m
CSA ¼ cross-sectional a
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402DISCUSS ION
In the current study, using the 3-vessel IVUS data
from the PROSPECT study, we analyzed the fre-
quency, morphology, and outcome of the largest
series of patients with ACS with secondary, non-
culprit plaque ruptures. The main ﬁndings of our
analysis are as follows. First, the prevalence of sec-
ondary, nonculprit plaque rupture was 14.1% and
was not different between patients with ST-segment
elevation myocardial infarction and patients with
non–ST-segment elevation myocardial infarction.US Findings in Lesions With Versus Without Plaque Rupture
Lesions With a
Plaque Rupture
(n [ 105)
Lesions Without a
Plaque Rupture
(n [ 3,124) p Value
29.7 (26.7–32.8) 15.4 (14.9–16.0) <0.0001
e, % 53.4 (52.5–54.3) 48.3 (48.0–48.5) <0.0001
3/mm 20.7 (19.6–21.7) 16.1 (15.9–16.4) <0.0001
m3/mm 9.6 (9.01–10.09) 8.4 (8.19–8.50) <0.0001
18.8 (15.3–22.6) 14.0 (10.4–17.9) <0.0001
6.3 (5.9–6.7) 6.5 (6.4–6.6) 0.40
9.5 (10) 20.1 (627) 0.008
66.0 (64.5–67.4) 56.0 (55.6–56.4) <0.0001
% 36.2 (38/105) 8.0 (250/3124) <0.0001
0.93 (0.90–0.96) 0.92 (0.91–0.92) 0.40
40.5 (37.9–43.2) 26.5 (25.9–27.2) <0.0001
m to MLA, mm 29.5 (25.0–34.0) 33.1 (32.1–34.1) 0.13
eans (95% conﬁdence interval), % (n), or % (n/N).
rea; EEM ¼ external elastic membrane; other abbreviations as in Table 2.Second, more than three-fourths of the plaque
rupture sites were part of a lesion that had the
phenotype of a ﬁbroatheroma, suggesting that this
may have been the rupture-prone morphological
precursor. Third, secondary, nonculprit plaque rup-
tures were associated with a greater prevalence of
other lesions with high-risk morphologies. Fourth,
patients with a nonculprit lesion plaque rupture had
a higher overall percent plaque volume with a greater
plaque burden at the MLA site as well as more VH-
TCFA lesions. Fifth, the incidence of overall
MACE was low, with no difference between pa-
tients with versus without silent plaque ruptures.
Frequency of secondary, nonculprit plaque ruptures.
In the ﬁrst 3-vessel IVUS study by Rioufol et al. (4),
the frequency of secondary, nonculprit plaque rup-
tures in patients with biomarker-positive ACS
was 79%. However, this was not substantiated by
a 3-vessel IVUS study from Hong et al. (3) or by
3-vessel optical coherence tomography studies from
Kubo et al. (10), Fujii et al. (11), or Tanaka et al.
(12), who reported rates of 12% to 31%. The current
study supports the lower prevalence of nonculprit
plaque ruptures in these latter studies, which is
consistent with pathological ﬁndings (13). Howev-
er, because IVUS of the culprit lesions was not
performed before the intervention, we cannot assess
the prevalence of secondary plaque ruptures ac-
cording to the underlying culprit lesion morphology,
that is, plaque rupture versus erosion versus calciﬁed
nodules.
Nevertheless, the current study extends the
ﬁndings of other studies to indicate that patients
with ACS who have secondary plaque ruptures have
additional lesions with high-risk morphologies,
albeit without frank plaque rupture, supporting the
Table 5. Three-Year Clinical Outcomes of Patients With Versus Without a
Plaque Rupture
Patient With at Least
1 Plaque Rupture
Lesion (n [ 93)
Patient Without
a Plaque Rupture
Lesion (n [ 567) p Value
Nonculprit lesion–related major
adverse cardiac events
15.0 (13) 11.6 (60) 0.35
Cardiac death 0.0 (0) 0.0 (0) NA
Cardiac arrest 0.0 (0) 0.0 (0) NA
Myocardial infarction 1.2 (1) 1.0 (5) 0.86
Rehospitalization 13.9 (12) 10.8 (56) 0.39
Values are Kaplan-Meier estimates expressed as % (n).
NA ¼ not applicable.
Table 4. IVUS-VH Findings in Lesions With Versus Without a Plaque Rupture
Lesions With a
Plaque Rupture
(n [ 105)
Lesions Without a
Plaque Rupture
(n [ 2,775) p Value
Volumetric data, %
Necrotic core volume 12.8 (11.5–14.1) 12.9 (12.4–13.5) 0.85
Dense calcium volume 6.0 (5.1–6.9) 6.5 (6.0–6.9) 0.33
Fibrous tissue volume 59.4 (58.1–60.7) 59.6 (59.0–60.1) 0.77
Fibrofatty volume 21.9 (20.2–23.6) 21.0 (20.3–21.8) 0.31
Lesion phenotype
VH-TCFA 38.1 (40) 21.7 (602) <0.0001
ThCFA 39.0 (41) 37.8 (1,050) 0.80
Pathological intimal thickening 19.0 (20) 36.8 (1,022) 0.0004
Fibrotic 3.8 (4) 2.5 (68) 0.38
Fibrocalciﬁc 0.0 (0) 1.2 (33) 0.38
Fibroatheroma subphenotype
VH-TCFA with multiple necrotic cores 32.4 (34) 15.3 (424) <0.0001
VH-TCFA with single necrotic core 5.7 (6) 6.4 (178) 0.80
Total VH-TCFA , mm 4.5 (3.3–5.7) 3.3 (3.0–3.6) 0.060
ThCFA with multiple necrotic cores 36.2 (38) 24.6 (684) 0.005
ThCFA with single necrotic core 2.9 (3) 13.2 (366) 0.007
Values are least squares means (95% conﬁdence interval) or % (n).
ThCFA ¼ thick-cap ﬁbroatheroma; other abbreviations as in Table 2.
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403hypothesis that this may represent a multifocal
phenomenon. Furthermore, the current study in-
dicates that patients with ACS who have secondary
plaque ruptures have a greater overall plaque burden
of the identiﬁed nonculprit lesions. Combining data
from 6 clinical trials that used serial IVUS, Nicholls
et al. (14) reported that the overall plaque burden
was a risk factor for future events (myocardial
infarction, coronary revascularization, or MACE)
during an average follow-up of 21 months.
Morphological ﬁndings. The criteria for the IVUS-
VH diagnosis of a TCFA have evolved from histo-
pathological concepts. In our current study, IVUS-VH
analysis revealed a residual conﬂuent necrotic core
(either at the bottom or shoulder of the cavity) in
62.5% of plaque ruptures, with 46.1% of plaque
ruptures having a VH-TCFA phenotype either
proximal or distal to the cavity. Although part of the
necrotic core may be expelled at the time of plaque
rupture, there is still a considerable amount of
residual necrotic core, and the amount of necrotic
core when comparing ruptures with nonruptures
(including nonﬁbroatheroma nonruptures) was
almost identical. Therefore, the pre-rupture lesion
should have had a larger necrotic core than the
nonruptures. This provides in vivo evidence sug-
gesting that the pre-rupture IVUS-VH morphology
may have been that of a ﬁbroatheroma.
Outcomes of secondary, nonculprit plaque ruptures.
Plaque rupture is the most common cause of ACS,
but as previously reported (3,4,10–12,15) and as also
seen in the current study, not all plaque ruptures
cause events. Fujii et al. (16) showed that plaque
ruptures cause symptoms in the setting of thrombus
formation and lumen compromise; comparing
culprit lesions with plaque ruptures in patients with
ACS versus nonculprit plaque ruptures in patients
with ACS versus plaque ruptures in patients with
stable angina, the MLA measured 3.3  1.5 mm2
versus 5.4  2.6 mm2 versus 6.1  2.0 mm2,
respectively, which helps explain why the secondary
plaque ruptures in the current study were “silent.”
Other studies have indicated that non–symptom-
producing plaque ruptures tend to heal and subse-
quently contributed to the development of a stenosis
(17,18).
Rioufol et al. (5) reported follow-up data in 14
patients with 28 secondary plaque ruptures without
signiﬁcant associated stenosis. All patients were
treated with statins and dual antiplatelet agents, and
there were no clinical events related to the non-
culprit rupture lesions. Hong et al. (6) also reported
12-month follow-up data in 28 patients with non-
stenotic ruptured plaques, one-half of which weretreated with statins. Complete healing of a ruptured
plaque was observed in 4 statin-treated patients
(29%) and in no non–statin-treated patients, and
target lesion revascularization was performed in
3 non–statin-treated patients (21%) but in no
statin-treated patients. A report by Ohlmann et al.
(7) also showed a low 5-year MACE rate relating to
secondary plaque rupture without luminal compro-
mise; in 17 patients, there was 1 death (6%) and
2 revascularizations (12%).
The current report is the largest series of patients
with secondary, nonculprit plaque ruptures. As in
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404previous studies, these lesions appear to be benign as
long as patients receive optimal medical therapy; in
the current study, 89.7% of patients were taking
aspirin and 83.3% of patients were taking statins
at 3 years. Furthermore, there was no difference in
outcomes between patients with versus without
secondary plaque ruptures.
Study limitations. First, in the current study, it is
likely that not all plaque ruptures were detected by
IVUS because the thickness of the thin ﬁbrous cap
is below the resolution of grayscale IVUS, so the
thrombus may obscure the ruptures. Second, this
study was a cross-sectional analysis of plaques at
different stages of development and evolution; serial
IVUS imaging was not performed as would be
necessary to prove the cause-and-effect relationship
between a TCFA and plaque rupture. Third,
because IVUS imaging was performed after suc-
cessful and uncomplicated percutaneous coronary
intervention of all lesions responsible for the index
event, the possibility cannot be excluded that
contrast injection, guidewire manipulation, or the
IVUS catheter itself might have created a ﬁssure in
the thin ﬁbrous cap to create the appearance of a
plaque rupture. Fourth, the culprit lesions were not
included in the current analysis because culprit le-
sions were stented before IVUS imaging. Fifth, the
current study used a 20-MHz IVUS probe with aresolution of approximately 200 mm and might have
missed small plaque ruptures compared with a
40-MHz IVUS probe (especially during saline
ﬂush) and even more so compared with optical
coherence tomography. Sixth, the diagnosis of
thrombus by IVUS is presumptive, especially when
using a 20-MHz solid-state device, and was not
reported in the PROSPECT study. Finally, event
rates were low in both groups and were too low to
detect a difference in mortality/morbidity.CONCLUS IONS
The current 3-vessel IVUS analysis of 660 patients
in the PROSPECT study showed that the preva-
lence of secondary, nonculprit plaque ruptures in
patients with ACS was 14.1%, that it was associated
with a VH ﬁbroatheroma phenotype with a residual
necrotic core in three-fourths of patients and a
VH-TCFA phenotype with a residual necrotic core
in approximately one-half of patients, and that it
was not associated with subsequent MACE in pa-
tients treated with proper medical therapy.
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